الفهرس Only 14 pages are availabe for public view
 |  | from | 236 |  |  |
| | | from | 236 | | |
Abstract
Chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis control. However, its extensive use in multiple reinfections and in non-infected individuals for prevention caused increase in parasite tolerance and/or resistance against this drug. Therefore, various studies have sought to identify new safe and effective drugs as alternatives to PZQ or in conjunction with PZQ to combat the growing threat of drug-resistant parasites. The novel enaminone derivative 4-hydroxyquinolin, (BDHQ), is an experimentally promising antischistosomal agent that has been proven to exhibit in vivo schistosomicidal effect and it has a lower toxicity than PZQ. Several studies reported that infection with Schistosoma mansoni causes an increase in oxidative stress as consequence of reactive oxygen species (ROS) generation. These ROS potentiate membranes lipid peroxidation and oxidative DNA damage